Impact of Oral Antibiotic Treatment on C. Difficile (C-Diff)
Exploratory Study of Impact of Oral Metronidazole, Vancomycin and Fidaxomicin on the Extent and Quantity of Host Carriage and Environmental Contamination With C. Difficile
Sponsor: Duke University
Listed as NCT02057198, this PHASE4 trial focuses on C. Difficile and Diarrhea and remains completed. Sponsored by Duke University, it has been updated 12 times since 2014, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
12 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE4
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE4
-
Nov 2019 — Jan 2021 [monthly]
Completed PHASE4
Phase: None → PHASE4
-
Jun 2018 — Nov 2019 [monthly]
Completed
▶ Show 7 earlier versions
-
May 2018 — Jun 2018 [monthly]
Completed
-
Apr 2018 — May 2018 [monthly]
Completed
Phase: NA → None
-
Dec 2017 — Apr 2018 [monthly]
Completed NA
Status: Recruiting → Completed
-
Aug 2017 — Dec 2017 [monthly]
Recruiting NA
-
Jun 2017 — Aug 2017 [monthly]
Recruiting NA
Phase: PHASE4 → NA
-
Feb 2017 — Jun 2017 [monthly]
Recruiting PHASE4
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE4
First recorded
Jun 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Duke University
For direct contact, visit the study record on ClinicalTrials.gov .